Moreover, an increase in PD-L1+ cells from baseline to Week 5 was noted across patients with DLBCL, suggesting that PD-L1 expression may be an adaptive increase in interferon signaling as a response of the tumor to immune engagement by the therapy [51]. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.